Avecho Biotechnology Limited has released a press release.
Positive interim results from Phase III insomnia program
Earlier from Avecho Biotechnology
- Receipt of Research & Development Tax Incentive
- Avecho completes treatment for Phase III interim analysis
- Expiry of Listed Options
- March 2026 Quarterly Activities Report & Appendix 4C